Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Tax Delay Doesn’t Make The Cut, But Issue Could Be Exhumed In Budget Conference

This article was originally published in The Gray Sheet

Executive Summary

Despite being a factor in lawmaker discussions throughout the shutdown, provisions to delay or repeal the device tax did not survive in the final agreement to reopen the federal government and raise the debt ceiling. But the issue appeared to gain more momentum than ever that companies hope can be maintained into upcoming budget conference talks.

You may also be interested in...



GOP, Dem Lawmakers Differ on Strategies To Repeal Device Tax

While Republican Congressman Pitts says he wants to inject language to repeal the 2.3 percent excise tax as part of a GOP ObamaCare “Off-Ramp” bill expected this summer, Democratic Senator Klobuchar says she is working on finding a pay for by the end of the year that would appease her Democratic colleagues and the White House.

Device Tax Repeal Without Offset May Surface In Tax Bills

Congress could attach a device tax repeal provision to a tax extenders bill moving through the Senate the weekend of Dec. 12-14, or future tax bills in the next Congress, but no pay-for provisions have been identified.

Industry Looking To New GOP Congress To Repeal Device Tax

AdvaMed says a new Congressional Research Service report underestimates the number of people likely to lose their jobs because of the tax and is looking forward to a new Republican Congress focused on repealing it.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel